X

Immuno Oncology

Immuno Oncology

The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies

This review aims to provide an overview of the current methodologies that are used to profile the TME, which may provide insights into the immunopathology associated...

11/22/2020
Society for Immunotherapy of Cancer Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups.

12/24/2020
`

Noninvasive Imaging of Cancer Immunotherapy

This study reviews recent developments in the field of noninvasive cancer imaging with a focus on immunotherapeutics and nuclear imaging technologies.

01/01/2021
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Exciting data from recent clinical trials have renewed interest in the field of cancer immunotherapy due to the potential of CAR NK cells in the production of “off-the-shelf” anti-cancer...

12/07/2020
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarker.

11/16/2020
TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.

Conventional dose finding designs in oncology drug development target on the identification of maximum tolerated (MTD), with assumption that MTD has...

Journal of Biopharmaceutical Statistics
09/20/2020
Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

Immuno-oncology and cell therapy, the frontier of cancer treatment, is a rapidly developing area that brings new opportunities to patients.

Contemporary Clinical Trials
09/01/2020
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology

The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored. Recently, several epigenetic drugs developed for cancer treatment described...

Epigenomes
09/10/2020
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

The B cell surface antigen CD19 is a target for treating malignancies, such as precursor acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Annals of Hematology
08/27/2020
Immuno-oncology cell therapy branches out

Optimization of CAR-T cell technology and application other immune types such as NK cells are tackling the efficacy, cost logistical challenges therapies for cancer....

Biopharma Dealmakers
09/01/2020
Multiomic analysis of cytokines in immuno-oncology.

Cytokines are a diverse group of peptides produced by different cell types including cancer cells and various subpopulations of immune system cells. 

Expert Review of Proteomics
10/31/2020
Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy

Engineered mammalian cells for medical purposes are becoming a clinically relevant reality thanks to advances in synthetic biology that allow enhanced reliability and safety of cell-based therapies

Vaccine
12/03/2020
Molecular Imaging in Immuno-Oncology: Current Status and Translational Perspectives.

Molecular imaging presents a prominent role for the management of oncological patients treated with ICIs.

Expert Review of Molecular Diagnostics
11/20/2020
Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes.

In this article, current literature on the use of RWE for regulatory submissions is reviewed, with a focus on novel anticancer immunotherapies, and discussion on the utility and...

Future Oncology
10/19/2020
A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition

This study aims to provide an overview of the recent advancements made in antibody-based approaches to the treatment of AML including monoclonal antibodies...

Best Practice &amp
11/04/2020
Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.

Hepatocellular carcinoma is a highly prevalent and lethal cancer that many therapeutics are being tested for this disease.

Clinics in Liver Disease
09/02/2020
Biotech and Breakthroughs in Immuno-Oncology.

The age of immuno-oncology has ushered in a rush within the biopharmaceutical industry.

Urologic Clinics of North America
09/09/2020
Statistical and practical considerations in designing of immuno-oncology trials

The novel mechanism of action immunotherapy agents, in treatment various types cancer, poses unique challenges during the designing clinical trials. It is important to account for possi......

Journal of Biopharmaceutical Statistics
09/10/2020
A concise review of bioanalytical methods of small molecule immuno-oncology drugs in cancer therapy.

Immuno-oncology (IO) is an emerging option to treat cancer malignancies.

Biomedical Chromatography
10/12/2020
Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment.

To better understand the influence of treatment of triple-negative mBC, a discrete choice experiment was designed to examine the influence of patient age, disease severity...

Future Oncology
09/21/2020
A perspective on HPK1 as a novel immuno-oncology drug target.

In this review, the role HPK1 in tumor immunity will be reviewed, with special emphasis on how T cells are negatively-regulated at different junctures of cancer-immunity...

eLife
09/08/2020
Design for immuno-oncology clinical trials enrolling both responders and nonresponders.

A typical challenge facing the design and analysis of immuno-oncology trials is prevalence nonproportional hazards patterns manifested in Kaplan-Meier curves under time-to-event endpoints. 

Statistics in Medicine
09/17/2020
Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.

The discussion within this study will be centered around the genetic foundations governing tumor immunity and molecular determinants associated with clinical benefit from ICI therapy. 

Human Molecular Genetics
10/07/2020
Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology

Immune checkpoint inhibitors (ICIs) are a novel treatment option for cancer therapy, which help direct the immune system to recognize and target cells.

Journal of the Formosan Medical Association
10/01/2020
Personalized Immuno-oncology.

Cancer immunotherapy aims to control the immune system eradicate cancer cells and prevent their spread.

Medical Principles and Practice
08/25/2020
Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment.

The immune checkpoint blockade represents a revolution in cancer therapy, with the potential to increase survival for many patients whom current treatments are not effective.

International Journal of Molecular Sciences
09/04/2020
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology

The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored.

Epigenomes
09/10/2020

source list reference

#7d60d9
#2694a4
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#42fc9a
#cc529a
#c59445
#c8cc0c
#e8085a
#97d1a0
#b61f77
#a153ac
#e7f6e3
#9a8c2c
#a9c507
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#49cde9
#c20fce
#d95d39